Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease
Sickle cell disease (SCD) is a monogenic inheritable disease characterized by severe anemia, increased hemolysis, and recurrent, painful vaso-occlusive crises due to the polymerization of hemoglobin S (HbS)-generated oxidative stress. Up until now, only four drugs are approved for SCD in the US. How...
Saved in:
Main Authors: | Waseem Chauhan (Author), Rahima Zennadi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications
by: Qinhong Wang, et al.
Published: (2021) -
KEAP1/NRF2 as a druggable target
by: Dinkova-Kostova Albena T.
Published: (2023) -
Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress
by: Shunhao Zhang, et al.
Published: (2022) -
Potential Benefits of Nrf2/Keap1 Targeting in Pancreatic Islet Cell Transplantation
by: Alberto Jarrin Lopez, et al.
Published: (2020) -
Keap1/Nrf2 Signaling Pathway
by: Gerasimos P. Sykiotis
Published: (2021)